A study published by the NIH Clinical Trials looked at vitamin C infusion as a possible treatment for severe COVID-infected pneumonia. The study was sponsored by ZhiYong Peng of the Zhongnan Hospital. The study hypothesized that vitamin C infusion could improve the prognosis of SARI (Severe acute respiratory infection)patients. 12g vitamin C was infused in the experimental group twice a day for 7 days by the infusion pump with a speed of 12ml/h. Early clinical studies have shown that vitamin C can effectively prevent the cytokine surge caused by sepsis, and neutrophils accumulation in the lungs destroying alveolar capillaries. In addition, vitamin C can help to eliminate alveolar fluid by preventing the activation and accumulation of neutrophils, and reducing alveolar epithelial water channel damage. At the same time, vitamin C can prevent the formation of neutrophil extracellular traps and shorten the duration of the common cold. In a controlled but non-randomized trial, 85% of the 252 students treated experienced a reduction in symptoms in the high-dose vitamin C group (1g / h at the beginning of symptoms for 6h, followed by 3 * 1g / day). Among patients with sepsis and ARDS, patients in the high-dose vitamin group did not show a better prognosis and other clinical outcomes.